Qube Research & Technologies (QRT)
CATX icon

Qube Research & Technologies (QRT)’s Perspective Therapeutics CATX Stock Holding History

Qube Research & Technologies (QRT)’s Portfolio CATX Stock Details CATX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-15,608
Closed -$65.1K – 3515
2026
Q1 		$65.1K Sell
15,608
-65,688
-81% -$278K ﹤0.01% 3137
2025
Q4 		$224K Buy
81,296
+12,337
+18% +$35.2K ﹤0.01% 3029
2025
Q3 		$237K Sell
68,959
-25,734
-27% -$93.8K ﹤0.01% 2906
2025
Q2 		$326K Sell
94,693
-27,320
-22% -$72.1K ﹤0.01% 2805
2025
Q1 		$260K Sell
122,013
-148,440
-55% -$445K ﹤0.01% 2783
2024
Q4 		$863K Buy
+270,453
New +$2.21M ﹤0.01% 2241
2024
Q3 		– Sell
-83,346
Closed -$831K – 3380
2024
Q2 		$831K Buy
83,346
+58,722
+238% +$849K ﹤0.01% 1969
2024
Q1 		$293K Buy
+24,624
New +$210K ﹤0.01% 2830

Other funds holding CATX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM

Qube Research & Technologies (QRT)'s CATX Position: Q2 2026 in Review

Qube Research & Technologies (QRT) sold out of Perspective Therapeutics (CATX) in Q2 2026, closing a stake of 15,608 shares — an estimated $65.1K sold.

Qube Research & Technologies (QRT) first reported a position in CATX in Q1 2024 and held it in 8 quarters. The position peaked at $863K in Q4 2024. 131 funds tracked by Wall St. Rank hold CATX as of Q2 2026.

  • Qube Research & Technologies (QRT) reported no remaining Perspective Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Qube Research & Technologies (QRT) sold 15,608 Perspective Therapeutics shares in Q2 2026, an estimated $65.1K.
  • Qube Research & Technologies (QRT) first reported a position in Perspective Therapeutics in Q1 2024 and held it in 8 quarters.
  • Qube Research & Technologies (QRT)'s Perspective Therapeutics position peaked at $863K in Q4 2024.
  • 131 funds tracked by Wall St. Rank held Perspective Therapeutics as of Q2 2026.

Based on Qube Research & Technologies (QRT)'s 13F filing for Q2 2026, filed 14 Aug 2026.